Comparison

Bortezomib European Partner

Item no. S1013-25
Manufacturer Selleckchem
CASRN 179324-69-7
Amount 25 mg
Category
Type Inhibitors
Specific against other
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias Velcade, LDP-341, MLM341, NSC 681239, Proteasome;Proteasome
Similar products Bortezomib
Available
Administration
Administered via i.v.
Animal Models
Mice are inoculated s.c. into the right flank with RPMI 8226 MM cells.
Cell lines
U266, IM-9, and Hs Sultan cells
Clinical Trials
Bortezomib is currently in Phase I/II clinical trials in patients with Non-small Cell Lung Cancer.
Concentrations
0-10 uM
Description
Bortezomib (PS-341, Velcade) is a potent proteasome inhibitor with Ki of 0.6 nM.
Dosages
<=1mg/kg
Formulation
Bortezomib is dissolved in 0.9% sodium chloride.
IC50
0.6 nM (Ki) [1], 0.6 nM (Ki) [1], 0.6 nM (Ki) [1], 0.6 nM (Ki) [1], 0.6 nM (Ki) [1], 0.6 nM (Ki) [1]
In vitro
Bortezomib has significant inhibitory effect on the growth of multiple myeloma (MM) cell lines including U266, IM-9, and Hs Sultan with IC50 of 3 nM, 6 nM and 20 nM, respectively. Proliferation of RPMI8226 MM cells resistant to conventional therapies are also inhibited by Bortezomib with IC50 of 30 nM, 40 nM, 20 nM and 20 nM for RPMI8226, Dox40, MR20, and LR5 cells, respectively. Furthermore, Bortezomib effectively inhibits the growth of four patients' MM cells (MM1–4) with IC50 of 3.5 nM, 5 nM, 30 nM, and 2.5 nM, respectively. [1]
In vivo
Bortezomib (0.5 mg/kg and 1.0 mg/kg) causes statistically significant inhibition of tumor growth and a statistically significant prolongation in median overall survival in RPMI8226 xenograft mouse model. [2]
Incubation Time
48 hours
Kinase Assay
Kinetic Methods, In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37 C by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 uL 10 uL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (lambdaex = 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Method
The inhibitory effect of Bortezomib on MM and BMSC growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 L of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 L of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.
Molecular Weight (MW)
384, 24
Picture ChemicalStructure Description
Bortezomib (Velcade) Chemical Structure
Picture Description 1
Data from [Carcinogenesis , 2010, 31, 19481955], Bortezomib (Velcade)purchased from Selleck, (BC) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 lg). The cells were then treated with Erlotinib (20 lM), Gefitinib (20 lM), Lapatinib (20 lM), CI-1033 (8 lM), LY294002 (20 lM) and Bortezomib (20 lM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (SD) of duplicate values of a representative experiment that was independently repeated for five times.
Picture Description 2
Data from [Development, 2011, 138, 2903-2908], Bortezomib (Velcade)purchased from Selleck, Control wild-type and Fmn2/oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1 M Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10 m.
Solubility (25C)
DMSO 77 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Storage
2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close